| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5474995 | MERCK | Phenyl heterocycles as cox-2 inhibitors |
Jun, 2013
(10 years ago) | |
| US6239173 | MERCK | 3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5H)-furanone as a cox-2 inhibitor |
Jun, 2013
(10 years ago) | |
|
US6239173 (Pediatric) | MERCK | 3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5H)-furanone as a cox-2 inhibitor |
Dec, 2013
(10 years ago) | |
|
US5474995 (Pediatric) | MERCK | Phenyl heterocycles as cox-2 inhibitors |
Dec, 2013
(10 years ago) | |
| US5691374 | MERCK | Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors |
May, 2015
(8 years ago) | |
|
US5691374 (Pediatric) | MERCK | Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors |
Nov, 2015
(8 years ago) | |
| US6063811 | MERCK | Compositions for a once day treatment of cyclooxygenase-2 mediated diseases |
May, 2017
(6 years ago) | |
|
US6063811 (Pediatric) | MERCK | Compositions for a once day treatment of cyclooxygenase-2 mediated diseases |
Nov, 2017
(6 years ago) | |
Vioxx is owned by Merck.
Vioxx contains Rofecoxib.
Vioxx has a total of 8 drug patents out of which 8 drug patents have expired.
Expired drug patents of Vioxx are:
- US5474995
- US6239173
- US6239173*PED
- US5474995*PED
- US5691374
- US5691374*PED
- US6063811
- US6063811*PED
Vioxx was authorised for market use on 20 May, 1999.
Vioxx is available in suspension;oral, tablet;oral dosage forms.
Vioxx can be used as signs and symptoms of osteoarthritis, rheumatoid arthritis in adults, and/or pauciarticular or polyarticular course juvenile rheumatoid arthritis, acute pain in adults; primary dysmenorrhea; and/or acute migraine attacks in adults, relief of the signs and symptoms of osteoarthritis; relief of the signs and symptoms of rheumatoid arthritis in adults; management of acute pain in adults; treatment of primary dysmenorrhea; acute treatment of migraine attacks in adults.
The generics of Vioxx are possible to be released after 06 November, 2017.
Drugs and Companies using ROFECOXIB ingredient
Market Authorisation Date: 20 May, 1999
Treatment: Signs and symptoms of osteoarthritis, rheumatoid arthritis in adults, and/or pauciarticular or polyarticular course juvenile rheumatoid arthritis, acute pain in adults; Primary dysmenorrhea; And/or ac...
Dosage: SUSPENSION;ORAL; TABLET;ORAL
VIOXX family patents
